Publications by authors named "John Dodd"

Claim this Profile
E
Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
David Evans, Kenneth Kenyon, George Ousler, Michael Watson, Patrick Vollmer, John Dodd

J Ocul Pharmacol Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel oral formulation of the melanocortin-1 receptor agonist PL8177 resolves inflammation in preclinical studies of inflammatory bowel disease and is gut restricted in rats, dogs, and humans.
John Dodd, Robert Jordan, Marie Makhlina, Keith Barnett, Ad Roffel

Front Immunol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pro-resolving and anti-arthritic properties of the MC selective agonist PL8177.
Jose Garrido-Mesa, Bethan Lynne Thomas, John Dodd, Carl Spana, Mauro Perretti

Front Immunol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration.
John Dodd, Robert Jordan, Marie Makhlina, Luana Pesco Koplowitz, Barry Koplowitz

Drugs R D· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases.
Carl Spana, Andrew W Taylor, David G Yee, Marie Makhlina, Wei Yang, John Dodd

Front Pharmacol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ((4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carbonyl)(propyl)carbamoyloxy)methyl-2-(4-(phosphonooxy)phenyl)acetate (BMS-751324), a Clinical Prodrug of p38α MAP Kinase Inhibitor.
Chunjian Liu, James Lin, John Hynes, Hong Wu, Stephen T Wrobleski, John H Dodd

J Med Chem· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and structure-activity relationships of novel indazolyl glucocorticoid receptor partial agonists.
John L Gilmore, James E Sheppeck, Jim Wang, T G Murali Dhar, Cullen Cavallaro, John H Dodd

Bioorg Med Chem Lett· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent and selective nonsteroidal indazolyl amide glucocorticoid receptor agonists.
James E Sheppeck, John L Gilmore, Hai-Yun Xiao, T G Murali Dhar, David Nirschl, John H Dodd

Bioorg Med Chem Lett· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The identification of novel p38α isoform selective kinase inhibitors having an unprecedented p38α binding mode.
Stephen T Wrobleski, Shuqun Lin, T G Murali Dhar, Alaric J Dyckman, Tianle Li, John H Dodd

Bioorg Med Chem Lett· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38α inhibitor.
Chunjian Liu, James Lin, Gerry Everlof, Christoph Gesenberg, Hongjian Zhang, John H Dodd

Bioorg Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).
Scott H Watterson, Charles M Langevine, Katy Van Kirk, James Kempson, Junquing Guo, John H Dodd

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Azaxanthene based selective glucocorticoid receptor modulators: design, synthesis, and pharmacological evaluation of (S)-4-(5-(1-((1,3,4-thiadiazol-2-yl)amino)-2-methyl-1-oxopropan-2-yl)-5H-chromeno[2,3-b]pyridin-2-yl)-2-fluoro-N,N-dimethylbenzamide (BMS-776532) and its methylene homologue (BMS-791826).
David S Weinstein, Hua Gong, Arthur M Doweyko, Mark Cunningham, Sium Habte, John H Dodd

J Med Chem· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38α MAP kinase inhibitors.
Alaric J Dyckman, Tianle Li, Sidney Pitt, Rosemary Zhang, Ding Ren Shen, John H Dodd

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cataracts in atopic dermatitis: a case presentation and review of the literature.
Brooke Bair, John Dodd, Karen Heidelberg, Kent Krach

Arch Dermatol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis.
Alaric J Dyckman, Charles M Langevine, Claude Quesnelle, James Kempson, Junqing Guo, John H Dodd

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-amino-pyrazoles as potent and selective p38α inhibitors.
Jagabandhu Das, Robert V Moquin, Alaric J Dyckman, Tianle Li, Sidney Pitt, John H Dodd

Bioorg Med Chem Lett· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dimethyl-diphenyl-propanamide derivatives as nonsteroidal dissociated glucocorticoid receptor agonists.
Bingwei V Yang, David S Weinstein, Lidia M Doweyko, Hua Gong, Wayne Vaccaro, John H Dodd

J Med Chem· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Utilization of a nitrogen-sulfur nonbonding interaction in the design of new 2-aminothiazol-5-yl-pyrimidines as p38α MAP kinase inhibitors.
Shuqun Lin, Stephen T Wrobleski, John Hynes, Sidney Pitt, Rosemary Zhang, John H Dodd

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Chunjian Liu, James Lin, Stephen T Wrobleski, Shuqun Lin, John Hynes, John H Dodd

J Med Chem· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel synthesis of the hexahydroimidazo[1,5b]isoquinoline scaffold: application to the synthesis of glucocorticoid receptor modulators.
Hai-Yun Xiao, Dauh-Rurng Wu, Mary F Malley, Jack Z Gougoutas, Sium F Habte, John H Dodd

J Med Chem· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase.
James Kempson, Junqing Guo, Jagabandhu Das, Robert V Moquin, Steven H Spergel, John H Dodd

Bioorg Med Chem Lett· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel tricyclic inhibitors of IkappaB kinase.
James Kempson, Steven H Spergel, Junqing Guo, Claude Quesnelle, Patrice Gill, John H Dodd

J Med Chem· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent pyrimidine inhibitors of phosphodiesterase 7 (PDE7) and their ability to inhibit T cell proliferation.
Junqing Guo, Andrew Watson, James Kempson, Marianne Carlsen, Joseph Barbosa, John Dodd

Bioorg Med Chem Lett· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Jagabandhu Das, Robert V Moquin, Sidney Pitt, Rosemary Zhang, Ding Ren Shen, John H Dodd

Bioorg Med Chem Lett· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Stephen T Wrobleski, Shuqun Lin, John Hynes, Hong Wu, Sidney Pitt, John Dodd

Bioorg Med Chem Lett· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis